196 related articles for article (PubMed ID: 6417770)
1. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
Heilesen AM; Permin H; Koch C; Høiby N
Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
[TBL] [Abstract][Full Text] [Related]
2. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Møller NE; Høiby N
Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636
[TBL] [Abstract][Full Text] [Related]
5. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
Fitzpatrick SB; Rosenstein BJ
Clin Pediatr (Phila); 1983 Sep; 22(9):628-30. PubMed ID: 6224623
[TBL] [Abstract][Full Text] [Related]
6. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
[TBL] [Abstract][Full Text] [Related]
7. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
Strandvik B; Malmborg AS; Alfredson H; Ericsson A
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Cabezudo I; Pfaller M; Bale M; Wenzel R
Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
[TBL] [Abstract][Full Text] [Related]
10. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Ciofu O; Giwercman B; Pedersen SS; Høiby N
APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime - a significant advance in the treatment of cystic fibrosis.
David TJ; Phillips BM; Connor PJ
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():337-40. PubMed ID: 6352639
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin.
Møller NE; Eriksen KR; Feddersen C; Flensborg EW; Høiby N; Norn S; Rosendal K; Schiøtz PO; Skov PS
Eur J Respir Dis; 1982 Mar; 63(2):130-9. PubMed ID: 6461561
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
Petrova G; Strateva T; Miteva D; Lazova S; Perenovska P
J Infect Dev Ctries; 2016 Nov; 10(11):1265-1267. PubMed ID: 27886041
[TBL] [Abstract][Full Text] [Related]
14. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Wu YL; Scott EM; Po AL; Tariq VN
APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
[TBL] [Abstract][Full Text] [Related]
16. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Prince AS; Neu HC
Antimicrob Agents Chemother; 1981 Oct; 20(4):545-6. PubMed ID: 6282199
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
18. The in-vitro activity of three anti-pseudomonal cephalosporins against isolates from patients with cystic fibrosis.
Kelly N; Falkiner FR; Keane CT; Murphy M; Fitzgerald MX
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():175-8. PubMed ID: 19802982
[TBL] [Abstract][Full Text] [Related]
19. Comparison between the in-vitro activity of new agents on Pseudomonas aeruginosa isolates from cystic fibrosis patients and other chronic infections.
Gordts B; Vandenborre C; VanderAuwera P; Butzler JP
J Antimicrob Chemother; 1984 Jul; 14(1):25-9. PubMed ID: 6434504
[TBL] [Abstract][Full Text] [Related]
20. [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].
Petit JC; Richard G; Burghoffer B; Daguet GL
Pathol Biol (Paris); 1982 Jun; 30(6):426-31. PubMed ID: 6810286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
